Evidence map›Paper›PMID 38196600›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after COPD Hospitalization among Older Adults.

Christopher L Mosher, Oyomoare L Osazuwa-Peters, Michael G Nanna, Neil R MacIntyre, Loretta G Que, W Schuyler Jones, Scott M Palmer, Emily C O'Brien

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Christopher L MosherDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-8463-1947
Oyomoare L Osazuwa-PetersDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC.
Michael G NannaSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.ORCID 0000-0001-5745-1636
Neil R MacIntyreDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC.
Loretta G QueDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC.
W Schuyler JonesDuke Clinical Research Institute, Durham, NC.ORCID 0000-0002-7288-9596
Scott M PalmerDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC.
Emily C O'BrienDuke Clinical Research Institute, Durham, NC.ORCID 0000-0002-8257-7561

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Generating novel predictive models to estimate the risk of future ASCVD & Dementia in older adultsR03AG074067 · NIA · YALE UNIVERSITY · PI NANNA, MICHAEL · 2021 to 2022
$335k
GEMSSTAR PERSPIRE-COPDR03AG082878 · NIA · DUKE UNIVERSITY · PI MOSHER, CHRISTOPHER · 2023 to 2024
$322k
NIA NIH HHS P30 AG021342NIA NIH HHS R03 AG074067NIA NIH HHS R03 AG082878
6 · The paper itself

Abstract

backgroundMeta-analyses have suggested the risk of atherosclerotic cardiovascular disease (ASCVD) events is significantly higher after a chronic obstructive pulmonary disease (COPD) exacerbation. However, these studies have been limited to highly selected patient populations potentially not generalizable to the broader population of COPD.

methodsWe assessed the risk of ASCVD hospitalizations after COPD hospitalization compared to before COPD hospitalization and identified patient factors associated with ASCVD hospitalizations after COPD hospitalization. This retrospective cohort study used claims data from 920,550 Medicare beneficiaries hospitalized for COPD from 2016-2019 in the US. The primary outcome was risk of a ASCVD hospitalization composite outcome (myocardial infarction, percutaneous coronary intervention, coronary artery by-pass graft surgery, stroke, or transient ischemic attack) in the 1 year after-COPD hospitalization relative to the 1 year before-COPD hospitalization. Time from discharge to a composite ASCVD hospitalization outcome was modeled using an extension of the Cox Proportional-Hazards model, the Anderson-Gill model with adjustment for patient characteristics. Additional analyses evaluated for interactions in subgroups and risk factors associated with the composite ASCVD hospitalization outcome.

resultsAmong 920,550 patients (mean age, 73 years) the hazard ratio estimate (HR; 95% CI) for the composite ASCVD hospitalization outcome after-COPD hospitalization vs before-COPD hospitalization was 0.99 (0.97, 1.02; p = 0.53) following adjustment. We observed 3 subgroups that were significantly associated with higher risk for ASCVD hospitalizations after COPD hospitalization: 76+ years old, women, COPD hospitalization severity. Among the 19 characteristics evaluated, 10 were significantly associated with higher risk of CVD events 1 year after COPD hospitalization with hyperlipidemia (2.78; 2.67, 2.90) and history of cardiovascular disease (1.77; 1.72 1.83) associated with the greatest risk.

conclusionAmong Medicare beneficiaries hospitalized for COPD, the risk of ASCVD hospitalizations was not significantly increased after COPD-hospitalization relative to before-COPD hospitalization. Although, we identified age 76+ years old, female sex, and COPD hospitalization severity as high risk subgroups and 10 risk factors associated with increased risk of ASCVD events after-COPD hospitalization. Further research is needed to characterize the COPD exacerbation populations at highest ASCVD hospitalization risk.

Identifiers

PMID38196600
PMCPMC10775335

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.